Home 2019-06-15T00:43:02+00:00

A Targeted Personalized Approach

Lantern is disrupting, reinventing and de-risking the traditional cancer drug development process by employing an adaptive '3R strategy' to rescue, reposition and revitalize abandoned drugs by harnessing the power of advanced genomics and artificial intelligence, also applicable for placing new drugs.

Download the white paper on Lantern’s AI -driven platform, RADR™ 3.0 and discover how we are leveraging AI to transform cancer therapy

In The Media

Career Opportunity at Lantern Pharma


3 Reasons The Health AI Market is a Great Investment: PrecisionMedicine using Genetic Signature Targeting – Arun Asaithambi Co-founder of Lantern Pharma Inc is featured in Entrepreneur.com

TiE Announces AI Driven Lantern Pharma as 2018 Top 50 Emerging Company
Lantern Pharma is excited to announce that it has been selected as a “2018 TiE50 winner” for the prestigious TiE50 Awards Program recognizing the world’s most innovative tech startups. This awards competition is part of TiE Inflect 2018, the world’s largest conference for tech entrepreneurs

Precision Oncology Company Lantern Pharma to Showcase Artificial Intelligence Approach

Lantern Pharma Joins Genomics England to Advance Their Precision Oncology Platform

Trusted Partners

We are collaborating, licensing and partnering with leading organizations to build a robust operational workflow and technology platform.

Partner With Us

We are a multi-national company committed to technology-driven drug candidate advancement. Join us in this mission.